Introduction: Results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) indicate that, with the exception of olanzapine, no substantial overall differences were identified between second generation antipsychotics (SGAs) and the first generation antipsychotic (FGA) perphenazine.
Methods: This study evaluated the effect of CATIE on antipsychotic prescribing. A retrospective review of 1807 adults with schizophrenia was conducted and relative quarterly percentages of FGA versus SGA prescriptions were calculated.
Results: Time series analysis did not identify significant differences in rates of FGA prescriptions.
Conclusions: Critiques of the methods used in CATIE may have mitigated its potential impact on antipsychotic prescribing despite cost-effectiveness of perphenazine treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.schres.2012.01.043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IUPHAR Themed Review: The Gut Microbiome in Schizophrenia.
Pharmacol Res
December 2024
UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia 5000, Australia. Electronic address:
Gut microbial dysbiosis or altered gut microbial consortium, in schizophrenia suggests a pathogenic role through the gut-brain axis, influencing neuroinflammatory and neurotransmitter pathways critical to psychotic, affective, and cognitive symptoms. Paradoxically, conventional psychotropic interventions may exacerbate this dysbiosis, with antipsychotics, particularly olanzapine, demonstrating profound effects on microbial architecture through disruption of bacterial phyla ratios, diminished taxonomic diversity, and attenuated short-chain fatty acid synthesis. To address these challenges, novel therapeutic strategies targeting the gut microbiome, encompassing probiotic supplementation, prebiotic compounds, faecal microbiota transplantation, and rationalised co-pharmacotherapy, show promise in attenuating antipsychotic-induced metabolic disruptions while enhancing therapeutic efficacy.
View Article and Find Full Text PDFAn Evaluation of Whether Routine QTc Interval Screening Is Necessary Prior to Starting ADHD Medications: Experience from a Large Retrospective Study.
Pediatr Rep
December 2024
Department of Pediatric Neurology, Queen Rania Children's Hospital, Royal Medical Services, Amman 11118, Jordan.
Background/objectives: Routine screening electrocardiograms (ECGs) prior to starting medications for attention-deficit/hyperactivity disorder (ADHD) remain controversial. This real-world study assessed corrected QT (QTc) interval data from pediatric patients who had a baseline ECG performed prior to initiating treatment with ADHD medications and ≥6 months of clinical follow-up.
Methods: A retrospective chart review of children aged 2-18 years diagnosed with ADHD with/without autism spectrum disorder (ASD) at child neurology clinics in Jordan (June 2019 and June 2021) was performed, and children were prescribed with ADHD medications to manage symptoms.
'Flattened, fattened, and forgotten': the 'dis-integrated' care of patients prescribed antipsychotics in the UK.
Br J Gen Pract
January 2025
Norie Millar Professor of General Practice, General Practice and Primary Care, School of Health and Wellbeing, University of Glasgow, Glasgow.
Assessment of factors associated with antipsychotic-induced weight gain: A nationwide cohort study.
Prog Neuropsychopharmacol Biol Psychiatry
December 2024
Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan. Electronic address:
Background: The incidence of antipsychotic-induced weight gain (AIWG) is difficult to predict in real-world practice because various factors influence it. This study aimed to explore background and medication-related factors associated with weight gain in patients newly prescribed with antipsychotic medication.
Methods: This nationwide, multicenter, prospective cohort study was conducted in Japan.
Early adolescent second-generation antipsychotic exposure produces long-term, post-treatment increases in body weight and metabolism-associated gene expression.
Pharmacol Biochem Behav
December 2024
Pennington Biomedical Research Center, Baton Rouge, LA 70808, United States of America.
The use of second-generation antipsychotic (SGA) medications in pediatric patients raises concerns about potential long-term adverse outcomes. The current study evaluated the long-term effects of treatment with risperidone or olanzapine on body weight, caloric intake, serum insulin, blood glucose, and metabolism-associated gene expression in C57Bl/6J female mice. Compared to mice treated with vehicle, female mice treated with risperidone or olanzapine gained weight at higher rates during treatment and maintained higher body weights for months following treatment cessation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!